<DOC>
	<DOCNO>NCT00686218</DOCNO>
	<brief_summary>RATIONALE : Panobinostat imatinib mesylate may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose panobinostat give together imatinib treat patient previously treat chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Panobinostat ( LBH589 ) Imatinib Mesylate Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety tolerability LBH589 give combination imatinib mesylate CML patient Major Cytogenetic Remission ( MCR ) residual BCR-ABL positive cell least 1 year daily imatinib mesylate treatment . - To determine maximum tolerate dose ( MTD ) dose-limiting toxicity LBH589 give combination imatinib mesylate CML patient . Secondary - To study effect LBH589 give combination imatinib mesylate cytogenetic response status BCR-ABL level CML patient major cytogenetic remission imatinib mesylate treatment . Tertiary - To study effect LBH589 give combination imatinib mesylate residual BCR-ABL positive primitive progenitor CML patient major cytogenetic remission imatinib mesylate treatment . OUTLINE : This dose-escalation study panobinostat . Patients receive oral panobinostat daily day 1 , 3 5 ; 8 , 10 , 12 ; 15 , 17 , 19 ; 22 , 24 , 26 . Patients also receive oral imatinib mesylate daily day 1-28 . Treatment repeat every 21 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month every 3 month 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Ability provide write informed consent obtain prior participation study relate procedure perform CML CP patient treat tolerated Imatinib 1 year , achieve least major cytogenetic response continue BCRABL positive ( Patients receive Imatinib dose 400 daily time entry study ) ANC PLT need normal range Serum albumin &gt; = 3g/dL AST/SGOT ALT/SGPT = &lt; 2.5 x upper limit normal ( ULN ) Serum bilirubin = &lt; 1.5 x ULN Serum creatinine = &lt; 1.5 x ULN 24hour creatinine clearance &gt; = 50 ml/min Serum potassium &gt; = low limit normal ( LLN ) Serum phosphorus &gt; = LLN Serum total calcium ( correct serum albumin ) serum ionized calcium &gt; = LLN Serum magnesium &gt; = LLN ECOG performance status = &lt; 2 Prior treatment HDAC inhibitor Patient treat Imatinib &lt; 1 year patient currently treat Imatinib dose &gt; 400 mg daily Impaired cardiac function include one following : Screening ECG QTc &gt; 450 msec ; Patients congenital long QT syndrome ; History presence sustain ventricular tachycardia ; Any history ventricular fibrillation torsades de pointes ; Bradycardia define heart rate &lt; 50 beat per minute ( patient pacemaker heart rate &gt; = 50 beat per minute eligible ) ; Patients myocardial infarction unstable angina within 6 month study entry ; Congestive heart failure ( NY Heart Association class III IV ) ; Right bundle branch block leave anterior hemiblock ( bifascicular block ) Uncontrolled hypertension Concomitant use drug risk prolong QT interval induce torsades de pointes Concomitant use CYP3A4 inhibitor Patients unresolved diarrhea &gt; CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Other concurrent severe and/or uncontrolled medical condition Patients receive chemotherapy , investigational drug undergone major surgery &lt; 4 week prior start study drug recover side effect therapy Concomitant use anticancer therapy radiation therapy Patients treat Coumadin ( unless patient require anticoagulation switch lowmolecular weight standard heparin ) Female patient pregnant breast feed patient reproductive potential willing use double method contraception include barrier method ( i.e . condom ) study 3 month end treatment ( Women childbearing potential [ WOCBP ] must negative serum pregnancy test within 7 day first administration oral LBH589 ) Male patient whose sexual partner WOCBP willing use double method contraception include condom study 3 month end treatment Patients history another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>